RxGenesys Biotechnology

TECHNOLOGY | rxgroup2

A new frontier of therapeutic and cosmetic breakthroughs through MicroRNA and iPS Cell applications | With global rights to a unique microRNA IPS Generation and Reprogramming technology, the RxGenesys Group aims to create groundbreaking initiatives to help overcome the current medical challenges in the areas of wound healing and tissue regeneration. Additionally, applications in topical cosmetic products have been clinically proven to provide unprecedented anti-aging benefits. | MicroRNAs (miRNA) are short 20- to 25-nucleotide (nt) long single-stranded noncoding RNAs that represent a class of small regulatory RNAs. Found in plants and animals, miRNAs regulate gene expression posttranscriptionally by triggering the degradation of target messenger RNAs (mRNA) and thus play an important role in a wide range of cellular processes.  | MicroRNA | microRNAs (miRNA) have been identified to play a critical role in ES cell maintenance and renewal. One of these miRNAs is found to be highly expressed in ES cells as compared to differentiated cells. So far our specifi miroRNA is known to target over 400 conserved genes in humans; these genes encode for proteins that function as developmental signals during differentiation processes in embryonic development. | Induced Pluripotent Stem Cells (iPS Cells) | Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka from Kyoto University, Japan, who showed in 2006 that the introduction of four specific genes could convert adult cells into pluripotent stem cells. As a result, he was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent.”  | ​ | ​